Is there an optimal irradiation dose for photodynamic therapy:  37 Jcm-2 or 75 Jcm-2?

B. Todd; A. Lesar; P. O'Mahoney; Ewan Eadie; Sally Ibbotson

doi:10.1111/bjd.18644

Is there an optimal irradiation dose for photodynamic therapy: 37 Jcm^-2 or 75 Jcm^-2?

B. Todd (Lead / Corresponding author)
, A. Lesar
, P. O'Mahoney
, Ewan Eadie
, Sally Ibbotson

Undergraduate Medicine

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

303 Downloads (Pure)

Abstract

Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).

Original language	English
Pages (from-to)	1287-1288
Number of pages	2
Journal	British Journal of Dermatology
Volume	182
Issue number	5
Early online date	2 Nov 2019
DOIs	https://doi.org/10.1111/bjd.18644
Publication status	Published - May 2020

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/bjd.18644

Author Accepted ManuscriptAccepted author manuscript, 2.55 MB
Author Accepted ManuscriptAccepted author manuscript, 2.56 MB

Cite this

@article{901f93482f6a4f6985d65c682b187358,

title = "Is there an optimal irradiation dose for photodynamic therapy: 37 Jcm-2 or 75 Jcm-2?",

abstract = "Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen{\textquoteright}s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).",

author = "B. Todd and A. Lesar and P. O'Mahoney and Ewan Eadie and Sally Ibbotson",

note = "{\textcopyright} 2019 British Association of Dermatologists.",

year = "2020",

month = may,

doi = "10.1111/bjd.18644",

language = "English",

volume = "182",

pages = "1287--1288",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Is there an optimal irradiation dose for photodynamic therapy

T2 - 37 Jcm-2 or 75 Jcm-2?

AU - Todd, B.

AU - Lesar, A.

AU - O'Mahoney, P.

AU - Eadie, Ewan

AU - Ibbotson, Sally

PY - 2020/5

Y1 - 2020/5

N2 - Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).

AB - Topical photodynamic therapy (PDT) is widely used for the treatment of Bowen’s disease (BD) and superficial basal cell carcinoma (BCC). The process involves oxygen‐dependent light activation of the tissue‐localised photosensitiser, protoporphyrin IX, three hours after pro‐drug application to the lesion. Current approved and licensed regimens involve application of either methylaminolevulinate (MAL, Metvix, Galderma, Switzerland) or 5‐aminolaevulinic acid in nanocolloid emulsion (ALA, Ameluz gel, Biofrontera, Germany) and subsequent light activation using narrow spectrum (630‐635 nm) red light (typically light emitting diodes (LEDs)), at an unweighted radiant exposure (“dose”) of 37 Jcm‐2 (1‐3).

UR - https://www.scopus.com/pages/publications/85076725611

U2 - 10.1111/bjd.18644

DO - 10.1111/bjd.18644

M3 - Letter

C2 - 31677268

SN - 0007-0963

VL - 182

SP - 1287

EP - 1288

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 5

ER -

Is there an optimal irradiation dose for photodynamic therapy: 37 Jcm^-2 or 75 Jcm^-2?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this